Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression

Abstract Background The early growth response 1 (EGR1) is a central transcription factor involved in systemic sclerosis (SSc) pathogenesis. Iguratimod is a synthesized anti-rheumatic disease-modifying drug, which shows drastic inhibition to EGR1 expression in B cells. This study is aiming to investi...

Full description

Bibliographic Details
Main Authors: Lichong Shen, Hanlin Yin, Li Sun, Zhiliang Zhang, Yuyang Jin, Shan Cao, Qiong Fu, Chaofan Fan, Chunde Bao, Liangjing Lu, Yifan Zhan, Xiaojiang Xu, Xiaoxiang Chen, Qingran Yan
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Arthritis Research & Therapy
Subjects:
Early growth response 1
Systemic sclerosis
Iguratimod
Anti-fibrotic
Xenograft
Online Access:https://doi.org/10.1186/s13075-023-03135-2

Internet

https://doi.org/10.1186/s13075-023-03135-2

Similar Items